Skip to main content
. 2015 May 21;5(2):165–173. doi: 10.3390/jpm5020165

Figure A1.

Figure A1

Progression-free survival of patients who had personalized therapy declined by insurance as compared to all other patients who underwent FoundationOne testing. Kaplan-Meier plot of progression-free survival in months for patients who applied for insurance reimbursement for personalized therapy based on FoundationOne result and had reimbursement declined (red line) as compared to all other patients who underwent FoundationOne testing (blue line). Progression-free survival was not significantly different between these groups (p = 0.334, Log Rank comparison). Cross-hatch lines represent data censored by the end of study period or when patient lost to follow up.